MiBA and Foundation Medicine Partner to Advance Genomic Profiling Utilization in Cancer Care

MiBA’s sophisticated platform for precision oncology empowers decision-makers throughout healthcare with the data and tools necessary to enable more accurate diagnoses and personalized treatment plans. These capabilities are integral components of MiBA’s comprehensive suite of services, reflecting its commitment to advancing healthcare insights on a broader scale. Through its strategic collaboration with Foundation Medicine, MiBA will help Foundation Medicine plan for and execute on CGP-related education programs for certain practices within the American Oncology Network.

"We are excited about the partnership between MiBA and Foundation Medicine as it presents a pivotal opportunity to elevate oncological care through education,” explains Andrew T. Fisher, MPH, MA, VP of Growth at MiBA. “This collaboration will focus on educational initiatives, providing healthcare professionals with the knowledge necessary to implement genomic profiling in clinical practice effectively.”

This partnership marks a promising step forward in the integration of CGP and resulting genomic data into everyday cancer treatment, reinforcing both organizations' dedication to innovation and excellence in oncology.

About Meaningful Insights Biotech Analytics: Precision Oncology Insights

MiBA is a healthcare AI technology company on a mission to close the feedback loop between physicians, patients, and industry partners. The technology and data insights that MiBA generates support pharmaceutical companies, research organizations, payers, biotech, health systems and providers to advance the quality of patient care. Learn more at mibanalytics.com and follow us on LinkedIn.